Summit Therapeutics (SMMT) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $15.37, +1.59% vs the prior close of $15.13.
- Volume 4.73M shares, 0.7x its 50-day average.
- New SEC filings: 4 (Oct 14, 2026).
- No new insider buys or sales reported since the prior session.
SMMT rises 1.6% to $15.37. Closed at $15.37, +1.59% vs the prior close of $15.13. Day range $15.08–$15.55, opened at $15.09.
SMMT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — SMMT rises 1.6% to $15.37
- Closed at $15.37, +1.59% vs the prior close of $15.13. Day range $15.08–$15.55, opened at $15.09.
- Volume was 4.73M shares, 0.7x its 50-day average of 6.51M.
- Price is -1.8% vs its 50-day average ($15.66) and -5.8% vs its 200-day average ($16.31).
- 52-week range $12.07–$29.23; today's close sits at 19% of that range, 47.4% below the 52-week high.
Oct 14, 2026 — SMMT dips 2.5% to $15.13, a 1-month low, 3 down days in a row
- Closed at $15.13, -2.51% vs the prior close of $15.52. Day range $15.04–$15.56, opened at $15.29.
- Volume was 4.66M shares, 0.7x its 50-day average of 6.50M.
- Price is -3.1% vs its 50-day average ($15.62) and -7.3% vs its 200-day average ($16.32).
- 52-week range $12.07–$29.23; today's close sits at 18% of that range, 48.2% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — SMMT slides 9.4% to $15.52
- Closed at $15.52, -9.40% vs the prior close of $17.13. Day range $15.47–$16.79, opened at $16.79.
- Volume was 7.13M shares, 1.1x its 50-day average of 6.43M.
- Price is -0.5% vs its 50-day average ($15.59) and -5.0% vs its 200-day average ($16.34).
- 52-week range $12.07–$29.23; today's close sits at 20% of that range, 46.9% below the 52-week high.
Oct 12, 2026 — SMMT dips 2.6% to $17.13
- Closed at $17.13, -2.62% vs the prior close of $17.59. Day range $17.05–$17.59, opened at $17.48.
- Volume was 4.37M shares, 0.7x its 50-day average of 6.42M.
- Price is +10.2% vs its 50-day average ($15.54) and +4.8% vs its 200-day average ($16.35).
- 52-week range $12.07–$29.23; today's close sits at 29% of that range, 41.4% below the 52-week high.
Oct 9, 2026 — SMMT rises 2.4% to $17.59
- Closed at $17.59, +2.45% vs the prior close of $17.17. Day range $16.82–$17.62, opened at $17.36.
- Volume was 5.75M shares, 0.9x its 50-day average of 6.38M.
- Price is +13.8% vs its 50-day average ($15.46) and +7.5% vs its 200-day average ($16.36).
- 52-week range $12.07–$29.23; today's close sits at 32% of that range, 39.8% below the 52-week high.
Oct 8, 2026 — SMMT slides 4.3% to $17.17
- Closed at $17.17, -4.35% vs the prior close of $17.95. Day range $16.80–$17.64, opened at $17.61.
- Volume was 6.17M shares, 1.0x its 50-day average of 6.33M.
- Price is +11.6% vs its 50-day average ($15.38) and +5.0% vs its 200-day average ($16.36).
- 52-week range $12.07–$29.23; today's close sits at 30% of that range, 41.3% below the 52-week high.
Oct 7, 2026 — SMMT jumps 3.7% to $17.95, 4 up days in a row
- Closed at $17.95, +3.70% vs the prior close of $17.31. Day range $16.98–$18.33, opened at $17.10.
- Volume was 8.17M shares, 1.3x its 50-day average of 6.27M.
- Price is +17.4% vs its 50-day average ($15.29) and +9.7% vs its 200-day average ($16.36).
- 52-week range $12.07–$29.23; today's close sits at 34% of that range, 38.6% below the 52-week high.
- That makes 4 straight gains.
Oct 6, 2026 — SMMT ends flat (+0.2%) to $17.31, 3 up days in a row
- Closed at $17.31, +0.23% vs the prior close of $17.27. Day range $16.53–$17.53, opened at $17.49.
- Volume was 5.87M shares, 0.9x its 50-day average of 6.24M.
- Price is +14.0% vs its 50-day average ($15.18) and +5.8% vs its 200-day average ($16.36).
- 52-week range $12.07–$29.23; today's close sits at 31% of that range, 40.8% below the 52-week high.
- That makes 3 straight gains.
Oct 5, 2026 — SMMT jumps 3.1% to $17.27
- Closed at $17.27, +3.07% vs the prior close of $16.75. Day range $16.44–$17.62, opened at $16.97.
- Volume was 5.28M shares, 0.8x its 50-day average of 6.29M.
- Price is +14.4% vs its 50-day average ($15.10) and +5.6% vs its 200-day average ($16.36).
- 52-week range $12.07–$29.23; today's close sits at 30% of that range, 40.9% below the 52-week high.
Oct 2, 2026 — SMMT rises 0.4% to $16.75
- Closed at $16.75, +0.39% vs the prior close of $16.69. Day range $16.66–$17.32, opened at $16.96.
- Volume was 5.19M shares, 0.8x its 50-day average of 6.26M.
- Price is +11.5% vs its 50-day average ($15.03) and +2.4% vs its 200-day average ($16.36).
- 52-week range $12.07–$29.23; today's close sits at 27% of that range, 42.7% below the 52-week high.
SMMT latest news & SEC filings
Every SEC filing by or about SMMT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Anand Bhaskar received an award of 100,000 shares on Oct 8, 2026; now holds 261,047
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 8.01 — Reported other events the company considers important.
Sep 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 26, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jul 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Jul 23, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 23, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$215.70M (prior year -$565.71M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.28 (prior year -$0.76) (loss narrowed vs Jun 30, 2025)
Jul 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade SMMT
- Last results release: Jul 23, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Feb 23, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Oct 22, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.89% (largest 9.4%).
- Liquidity: about 7.40M shares (≈$113.71M) trade per day on average.
- 52-week position: $15.37 vs a range of $12.07–$29.23 (19% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 9 open-market buys, 0 sales; latest: Robert W Duggan bought 3,810,000 shares on Jun 12, 2026.
- Latest filings: 8-K Sep 29, 2026; 8-K Sep 15, 2026; 8-K Sep 14, 2026.
- Share count: 797.75M shares outstanding (Jul 17, 2026), +7.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
SMMT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 15.09 | 15.55 | 15.08 | 15.37 | 4.73M |
| Oct 14, 2026 | 15.29 | 15.56 | 15.04 | 15.13 | 4.66M |
| Oct 13, 2026 | 16.79 | 16.79 | 15.47 | 15.52 | 7.13M |
| Oct 12, 2026 | 17.48 | 17.59 | 17.05 | 17.13 | 4.37M |
| Oct 9, 2026 | 17.36 | 17.62 | 16.82 | 17.59 | 5.75M |
| Oct 8, 2026 | 17.61 | 17.64 | 16.80 | 17.17 | 6.17M |
| Oct 7, 2026 | 17.10 | 18.33 | 16.98 | 17.95 | 8.17M |
| Oct 6, 2026 | 17.49 | 17.53 | 16.53 | 17.31 | 5.87M |
| Oct 5, 2026 | 16.97 | 17.62 | 16.44 | 17.27 | 5.28M |
| Oct 2, 2026 | 16.96 | 17.32 | 16.66 | 16.75 | 5.19M |
| Oct 1, 2026 | 16.82 | 17.50 | 16.59 | 16.69 | 7.90M |
| Sep 30, 2026 | 16.59 | 17.72 | 16.17 | 16.91 | 13.06M |
| Sep 29, 2026 | 18.91 | 19.09 | 16.15 | 16.39 | 27.34M |
| Sep 28, 2026 | 15.50 | 15.82 | 15.18 | 15.48 | 6.15M |
| Sep 25, 2026 | 16.45 | 16.58 | 15.55 | 15.61 | 3.80M |
| Sep 24, 2026 | 16.37 | 16.78 | 16.09 | 16.38 | 5.04M |
| Sep 23, 2026 | 17.10 | 17.46 | 16.25 | 16.45 | 3.89M |
| Sep 22, 2026 | 16.97 | 17.50 | 16.79 | 17.12 | 4.62M |
| Sep 21, 2026 | 18.40 | 18.42 | 16.64 | 16.90 | 5.78M |
| Sep 18, 2026 | 17.74 | 17.87 | 17.31 | 17.85 | 13.06M |
About Summit Therapeutics
Summit Therapeutics (SMMT) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in MIAMI, FL. Fiscal year ends December 31. SEC CIK 1599298.
SMMT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Robert F. Booth | Director | Jan 6, 2026 |
| Alessandra Cesano | Director | Jan 6, 2026 |
| Kenneth A Clark | Director | Jan 6, 2026 |
| Robert W Duggan | Co-Chief Executive Officer | Jun 12, 2026 |
| Jeff Huber | Director | Jan 6, 2026 |
| Mostafa Ronaghi | Director | Jan 6, 2026 |
| Manmeet Singh Soni | COO and CFO | Jun 4, 2026 |
| Yu Xia | Director | Jan 6, 2026 |
| Mahkam Zanganeh | Co-Chief Executive Officer | Jun 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Bhaskar Anand | Chief Accounting Officer | Jan 12, 2026 |
| Robert W Duggan | Co-Chief Executive Officer | Jun 12, 2026 |
| Manmeet Singh Soni | COO and CFO | Jun 4, 2026 |
| Mahkam Zanganeh | Co-Chief Executive Officer | Jun 12, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 12, 2026 | Robert W Duggan | Buy | 3,810,000 | $13.12 |
| Jun 12, 2026 | Mahkam Zanganeh | Buy | 3,810,000 | $13.12 |
| Jun 4, 2026 | Mahkam Zanganeh | Buy | 100,000 | $14.60 |
| Jun 4, 2026 | Robert W Duggan | Buy | 100,000 | $14.60 |
| Jun 4, 2026 | Manmeet Singh Soni | Buy | 25,000 | $14.43 |
| Jun 4, 2026 | Manmeet Singh Soni | Buy | 25,000 | $14.46 |
| Oct 21, 2025 | Mahkam Zanganeh | Buy | 26,680 | $18.74 |
| Oct 21, 2025 | Yu Xia | Buy | 533,617 | $18.74 |
| Oct 21, 2025 | Robert W Duggan | Buy | 26,680 | $18.74 |
SMMT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-1.08B | -1.44 | $-322.93M |
| Dec 31, 2024 | $0 | $-221.31M | -0.31 | $-142.11M |
| Dec 31, 2023 | $0 | $-614.93M | -0.99 | $-76.76M |
| Dec 31, 2022 | $705.00K | $-78.78M | -0.41 | $-41.58M |
| Dec 31, 2021 | $1.81M | $-88.60M | -0.67 | $-72.59M |
Latest balance sheet: total assets $752.18M, total liabilities $122.20M, cash $419.37M (as of Jun 30, 2026).
SMMT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 23, 2026 | 8-K Item 2.02 (results) | $14.98 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $21.46 |
| Feb 23, 2026 | 8-K Item 2.02 (results) | $16.09 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $17.04 |
| Oct 20, 2025 | 8-K Item 2.02 (results) | $20.03 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $28.25 |
| May 1, 2025 | 8-K Item 2.02 (results) | $24.67 |
| Feb 24, 2025 | 8-K Item 2.02 (results) | $18.84 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $18.17 |
| Oct 30, 2024 | 8-K Item 2.02 (results) | $18.65 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 1, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on SMMT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.